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Abstract
Background: Gastrin-releasing peptide receptor antagonists have promise in theranostics of several highly incident
tumours, including prostate and breast. This study presents the first human dosimetry of 68Ga-NODAGA-MJ9 in the
first five consecutive patients with recurrent prostate cancer included in a dual-tracer positron emission
tomography (PET) protocol. Five male patients with biochemical relapse of prostate adenocarcinoma underwent
four whole-body time-of-flight PET/CT scans within 2 h after tracer injection. To be used as input in OLINDA/EXM 2.
0, time-integrated activity coefficients were derived from manually drawn regions of interest over the following
body regions: brain, thyroid, lungs, heart, liver, gallbladder, spleen, stomach, kidneys, adrenals, red marrow, pancreas,
intestines, urinary bladder and whole body. Organ absorbed doses and effective dose (ED) were calculated with
OLINDA/EXM 2.0 using the NURBS voxelized phantoms adjusted to the ICRP-89 organ masses and ICRP103 tissue-
weighting factors. Additional absorbed dose estimations were performed with OLINDA/EXM 1.1 to be comparable
with similar previous publications.
Results: The body regions receiving the highest absorbed doses were the pancreas, the urinary bladder wall, the
small intestine and the kidneys (260, 69.8, 38.8 and 34.8 μGy/MBq respectively). The ED considering a 30-min urinary
voiding cycle was 17.6 μSv/MBq in male patients. The increment of voiding time interval produced a significant
increase of absorbed doses in bladder, prostate and testes, as well as an increase of ED. ED also increased if
calculated with OLINDA/EXM 1.1. These results have been discussed in view of similar publications on bombesin
analogues or on other commonly used theranostic peptides.
Conclusions: The pancreas is the most irradiated organ after the injection of 68Ga-NODAGA-MJ9, followed by the
urinary bladder wall, the small intestine and the kidneys. ED is in the same range of other common 68Ga-labelled
peptides. Differences with similarly published studies on bombesin analogues exist, and are mainly dependent on
the methodology used for absorbed dose calculations.
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Background
The amphibian skin is a quasi-unlimited source of
biologically active peptides, which have been the ob-
ject of extensive pharmacological studies in the past
decades [1]. Most of these peptides have their coun-
terparts in vertebrate brain and gastrointestinal tract,
an occurrence that has been named as the “brain-
gut-skin triangle” [2]. A striking example of such tri-
angle is the tetradecapeptide bombesin, which was
isolated from the skin of the European amphibians
Bombina bombina and Bombina variegata [3] several
years before the identification and sequencing of its
mammalian analogue, named gastrin-releasing peptide
(GRP) [4]. Yet, the name GRP might not be fully ap-
propriate, as bombesin and its human analogue exert
a wide range of biological effects, including release of
hormones from gastrointestinal and endocrine organs,
contraction of smooth muscles, as well as central
regulation of temperature and circadian rhythms [5].
In addition, GRP modulates the function of immune
cells and, most importantly, it acts as an autocrine
growth factor in several tumour types, including lung
[6] and prostate cancer [7]. The mitotic activity of
GRP in human tumours is largely mediated by the
G-protein-coupled receptor BB2, also known as
GRP-receptor (GRPR); interestingly, the interference
with GRPR-mediated functions produces significant
anti-mitotic effects [5, 8]. It follows that the applica-
tion of GRPR-targeting, radiolabelled bombesin ana-
logues to the imaging and treatment of various
neoplasms has raised considerable interest over the
past 20 years [9].
Most of these research efforts have regarded prostate
cancer, given the high density of GRPR since the early
phase of neoplastic transformation [10]. The first radio-
active bombesin analogues successfully used in prostate
cancer patients were technetium-labelled GRPR agonists
[11, 12]. It was later realised that, despite poor internalisa-
tion, GRPR antagonists might be advantageous over GRPR
agonists because of the lack of pharmacological effects
and better tumour-to-background ratios, through a higher
number of binding sites or a higher affinity [13]. The in-
creasing clinical use of positron-emitting radionuclides for
tumour imaging has prompted researchers to develop
newer GRPR antagonists labelled with 68Ga, 18F, or 64Cu
[14], and it has been recently suggested that GRPR might
complement prostate-specific membrane antigen (PSMA)
for prostate cancer imaging [15].
The aim of the present study was to assess the human
dosimetry of the GRPR antagonist 68Ga-NODAGA-4-ami-
no-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-G
ly-His-Sta-Leu-NH2 (NODAGA-MJ9) [16] in the first five
patients with recurrent prostate cancer included in a
dual-tracer positron emission tomography (PET) protocol.
Materials and methods
Patients
This dosimetry sub-study was designed to enrol the first
five consecutive patients recruited in an imaging study
comparing 18F-Fluorocholine and 68Ga-NODAGA-MJ9
as restaging modalities for prostate cancer in biochem-
ical relapse (clinicaltrial.gov identifier NCT02111954,
start date: April 2014). Aim of the dosimetry sub-study
was to provide human absorbed dose estimations for
68Ga-NODAGA-MJ9, whereas dosimetry of 18F-Fluoro-
choline is already reported elsewhere [17]. Eligible pa-
tients presented a histologically confirmed prostate
adenocarcinoma in biochemical relapse after a primary
curative treatment (defined as prostate-specific antigen,
PSA > 0.5 ng/mL after radical prostatectomy or with
the nadir + 2 ng/mL definition after a primary radio-
therapy [18]) for which 18F-Fluorocholine PET/CT was
requested as restaging modality. Exclusion criteria were
represented by the inability to provide written informed
consent, age < 18 years and ongoing androgen
deprivation therapy. The Ethical Committee of Canton
Vaud, Swissmedic and the Federal Office of Public
Health (FOPH), authorised the study. Patients gave
separate written informed consent to the clinical and
the dosimetry protocols before radiopharmaceutical
administration.
Radiochemistry
The NODAGA-MJ9 peptide was produced as a GMP
product by CS Bio Co (Menlo Park, CA, USA).
NODAGA-MJ9 was radiolabelled with the 68Ga eluate
of a 68Ge-generator IGG100 (Eckert & Ziegler, Germany)
using cassettes C4-GA68-FR on an automatic synthesis
unit, Modular-Lab PharmTracer (Eckert & Ziegler,
Germany). 68Ga was eluted with 0.1 mol/L HCl.
NODAGA-MJ9 (20 μg) was radiolabelled with the high
activity 68GaCl3 fraction (2 mL, 200–1300 MBq) by in-
cubation for 20 min at room temperature. After
C18-cartridge (Sep-Pak) pre-concentration,
68Ga-NODA-
GA-MJ9 was eluted with 50% aqueous ethanol (0.8 mL)
through a 0.22 μm sterile filter, and the cartridge and fil-
ter were rinsed with sterile 0.9% NaCl solution (7 mL).
High-pressure liquid chromatography (HPLC) analysis
was performed at 220 nm on a μ-Bondapak column
(Waters C18, 3.9 × 300 mm) by gradient elution (solvent
A: 0.01 M TFA, solvent B: CH3CN/H2O:7/3 + TFA, 8/2
for 2 min then increase to 1/9 in 8 min at 1.2 mL/min).
Thin-layer chromatography (TLC) was performed using
sodium acetate 1M in MeOH 1:1 on an activated
iTLC-SG plate, with detection using a mini-Gita TLC
scanner (Elysia-Raytest). Prior to release, all quality con-
trols requested by the Swiss Federal authorities were
met for a human injectable.
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PET/CT acquisition protocol
Four whole-body PET scans (from top of the skull to
mid femoral bone, 2 min/bed position) were acquired on
a Discovery 690 time-of-flight (TOF) PET/CT (GE
Healthcare, Waukesha, Wisconsin, USA) 15 ± 2, 45 ± 2,
70 ± 5 and 100 ± 4 min after the intravenous administra-
tion of 113 ± 21 MBq 68Ga-NODAGA-MJ9. Patients
were asked to void between scans (30-min voiding cycle).
The list-mode acquisition integrating TOF information
and point-spread-function recovery was reconstructed
with a proprietary three-dimension ordered subset expect-
ation maximisation (3D-OSEM) algorithm (GE-VPFXS, 3
iterations × 16 subsets) including a FWHM = 5 mm
Gaussian post-reconstruction filter [19]. All pertinent
image corrections (normalisation, dead time, activity
decay, random coincidence and attenuation and scatter
corrections) were applied. The acquired field of view size
was 70 cm reconstructed in a 256 × 256 image matrix. Re-
constructed voxel size was 2.73 × 2.73 mm in the trans-
verse plane and 3.27 mm in the axial direction.
Morphologic information was obtained from CT scan:
120 kVp, 60 mA and pitch = 3; CT FOV diameter:
700 mm; reconstructed image matrix size: 512 × 512; pixel
spacing: 1.37 × 1.37 mm; and slice thickness: 3.75 mm.
As previously described, quantitative accuracy for 68Ga
PET/CT was assessed to be within 6% of the expected
value [20].
Organ segmentation
Co-registered PET and CT data were loaded using
PMOD (PMOD Technologies, Zurich, Switzerland). In
PMOD, the CT matrix is used as reference for spatial re-
sampling of PET data. Volumes of interest (VOI) were
manually drawn slice by slice on the axial plane of the
CT part of each PET/CT study using the polygonal seg-
mentation tool of PMOD by two operators in consensus
(SG and FC) for the following body regions: brain, thy-
roid, lungs, heart, liver, gallbladder, spleen, stomach, kid-
neys, adrenals, red marrow, intestines and whole body.
Pancreas and urinary bladder were manually seg-
mented on the emission PET data.
CT-based segmentation of the bladder would have not
taken into account possible changes of volume due to
bladder filling during the PET/CT acquisition time.
Manual segmentation of the pancreas based on the
emission data was adopted to recover the actual organ
activity by compensating for signal spill-out from the
organ. No specific activity threshold was adopted for
segmentation based on emission data. However, we esti-
mated that the volume identified by our segmentation
method corresponded to the volume that would result if
a 5% of maximum activity threshold was adopted (data
not shown).
Absorbed dose estimations
The total activity contained in each considered source
organ was obtained by multiplication of the average ac-
tivity concentration (expressed in Bq/mL) by the organ
volume expressed in mL. Measured activity in source
organs at each time point was normalised to the admin-
istered patient activity. For all source organs but the
gallbladder, a mono-exponential fit extended to infinite
beyond the last measured data point was used to derive
time-integrated activity coefficients (TIACs) by time-in-
tegration of source organ time-activity curves. The
goodness of fit for each organ was expressed by the R2
metric. In the gallbladder, radioactivity was still in the
uptake phase at the last time point image. Therefore,
between t = 0 and t = 100 min, the TIAC was obtained
by trapezoidal integration using Matlab software
(Release 2017a, The MathWorks, Inc., Natick, Massa-
chusetts, USA), whereas a mono-exponential analytical
integration to infinite was calculated after the last
measure, assuming the 68Ga physical decay. This
approach can be considered largely conservative
because it does not take into account the physiological
voiding of the gallbladder content that would naturally
occur within a few hours, and that would reduce the
effective tracer half-life in the organ.
Bone marrow dosimetry was estimated by drawing
three red marrow VOIs, in the head of humeral bone, in
the heads of the femoral bone and in the lumbar verte-
brae L3-L4, respectively. The total number of disintegra-
tions in the bone marrow was calculated by multiplying
the average number of disintegrations within these three
VOIs by the red marrow mass of the ICRP-89 adult male
reference phantom [21]. To estimate the absorbed dose
to the colon, the total number of disintegrations in this
organ was partitioned to its components (right colon,
left colon and rectum) proportionally to their respective
masses of the ICRP-89 male reference phantom [21].
Organ TIACs were used in input to the OLINDA/
EXM® 2.0 (HERMES Medical Solution AB, Stockholm,
Sweden) code [22]. OLINDA/EXM 2.0 provided organ-
absorbed doses and effective dose (ED) per absorbed ac-
tivity in μGy/MBq and μSv/MBq, respectively, using the
NURBS voxel-based phantoms [23] adjusted to the
ICRP-89 organ masses [21] and ICRP103 tissue weight-
ing factors (wT) [24]. Differences in organ absorbed
doses estimated by varying the urinary voiding cycle in
the range 0.5–3.5 h were assessed using two-sided un-
paired Student’s t test.
By using the reference organ masses of OLINDA/EXM
2.0, we adopted a methodological approach typical of ra-
dioprotection, where the dosimetry of a reference adult
subject is the major concern. Nevertheless, patient-specific
dosimetry has also been performed and provided as
Additional file 1: Table S1.
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In order to calculate the ED for the reference per-
son, and in view of possible applications of GRPR tar-
geting in breast cancer [11, 25–27], we simulated
organ absorbed doses and ED for female patients.
Accordingly, TIACs derived from our male patients
were entered in OLINDA/EXM 2.0 and applied to the
organ masses of the adult female phantom. The ED
for the reference person was automatically computed
by the OLINDA/EXM 2.0 code using both male and
female equivalent organ doses according to the ICRP
103 methodology.
Comparison with previous studies
To facilitate the comparison with previous similar publi-
cations on dosimetry of bombesin analogues [28–34], we
performed an additional absorbed dose estimation using
our TIACs in input to OLINDA/EXM 1.1, which imple-
ments the Cristy & Eckerman phantoms [35] and
ICRP-60 tissue wT [36]. Absorbed dose calculations were
performed using either a 1-h or a 3.5-h urinary voiding
cycle, to allow direct comparison between our results
and those of other authors using 68Ga-labelled bombesin
analogues [30, 33, 34].
Results
Patients
Five prostate cancer patients (mean age 65, range 56–
72 years) with biochemical relapse after radical prosta-
tectomy with or without postoperative radiotherapy were
enrolled between April and May 2014. One patient had
history of pancreatic adenocarcinoma treated with pan-
creaticoduodenectomy and adjuvant radiochemotherapy,
in clinical remission at the time of inclusion. Two pa-
tients had undergone cholecystectomy due to gallstones.
Table 1 summarises patients’ characteristics and the
main 68Ga-NODAGA-MJ9 PET/CT findings. Prelimin-
ary results of the comparison between 18F-Fluorocholine
and 68Ga-NODAGA-MJ9 in the relapse setting were
previously reported in an abstract form [37]. Definitive
results of the main clinical study are not yet available
and will be reported elsewhere.
Radiochemistry
The 68Ga-NODAGA-MJ9 radiochemical purity was ≥ 95%
by iTLC and < 5% free Gallium. By HPLC, the radiochem-
ical purity was ≥ 95% 68Ga-NODAGA-MJ9 with a reten-
tion time of 9.0 min. There was less than 0.001% 68Ge
radionucleidic impurity. The synthesis time of 68Ga-NO-
DAGA-MJ9 was 33 min overall. The specific activity at
end of synthesis (EOS) was 6–40 GBq/mg, with a
peptide weight of 20 μg. The volumetric activity EOS
was 15–103 MBq/mL.
Imaging
All injections were well-tolerated. No immediate symp-
toms or modification of vital signs were observed. Typical
biodistribution of 68Ga-NODAGA-MJ9 is shown in Fig. 1.
The radiopharmaceutical is excreted via both urinary and
hepato-biliary routes. Urinary bladder uptake is seen as
early as 15 min after injection. No radiopharmaceutical re-
tention is observed in the renal cortex, while the gallblad-
der is still in the biological uptake phase at the last
imaging time point, 100 min after injection. A high and
homogeneous pancreatic tracer uptake is seen.
Absorbed dose estimations
Time-activity curves for relevant abdominal organs are
shown in Fig. 2. Organ time-activity curves corrected for
68Ga physical decay are shown in Fig. 3. Measured
TIACs, organ absorbed doses and ED of the patients en-
rolled, as well as the extrapolated values to female and
reference person, are reported in Table 2.
The organ receiving the highest absorbed dose was the
pancreas (260 μGy/MBq), followed by the urinary blad-
der wall, the small intestine and the kidneys (69.8, 38.8
and 34.8 μGy/MBq respectively).
Using a 30-min urinary voiding cycle, we obtained an
ED of 17.6 μSv/MBq in our male patients. The extrapo-
lation to 1-h voiding cycle resulted in EDs of 18.8 and
23.0 μSv/MBq for male and female, respectively. The
corresponding ED for the reference person was
21.7 μSv/MBq.
The increment of voiding time interval produced a sig-
nificant increase of absorbed doses in the following
Table 1 Patient characteristics
Patient Age (years) BMI (kg/m2) Gleason score PSA (ng/ml) PSA doubling time (months) 68Ga-MJ9 PET/CT findings
1 62 31.4 9 8.5 2 Lymph nodes + bone metastases
2a 68 22.1 7 2.3 1 Bone metastases
3b 67 27.5 6 3.4 18 Bone metastases
4b 72 24.9 9 7.7 4.4 Lymph-nodal metastases
5 56 24.3 8 7.3 12 Local relapse
aHistory of pancreatic carcinoma treated with pancreaticoduodenectomy, and adjuvant chemo- and radiotherapy
bHistory of gallstones treated with cholecystectomy
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organs: urinary bladder wall (+ 60% for 1-h vs. 0.5-h
voiding cycle, p = 0.001, and + 186% for 3.5-h vs. 0.5-h
voiding cycle, p < 0.0001), prostate (+ 9% for 1-h vs.
0.5-hvoiding cycle, p = 0.034, and + 29% for 3.5-h vs.
0.5-h voiding cycle, p < 0.0001) and testes (+ 2% for 1-h
vs. 0.5-h voiding cycle, p = 0.48, and + 8.5% for 3.5-h vs.
0.5-h voiding cycle, p = 0.039). ED increased as well with
the voiding time interval (+ 7% for 1-h vs. 0.5-h voiding
cycle, p = 0.032, and + 33% for 3.5-h vs. 0.5-h voiding
cycle, p < 0.0001).
Comparison with previous studies
Results of our absorbed dose estimations performed with
OLINDA/EXM 1.1 assuming 1-h and 3.5-h voiding cy-
cles are reported as Additional file 2: Table S2.
Fig. 1 Maximum intensity projections acquired 10, 45, 70 and 100 min after 68Ga-NODAGA-MJ9 injection (a–d, respectively) in a 56-year-old
patient with biochemical relapse of prostate cancer (patient #5). The typical 68Ga-NODAGA-MJ9 biodistribution is observed, including visualisation
of the urinary system, as well as fast and prominent uptake by the pancreas and the biliary tract
Fig. 2 68Ga-NODAGA-MJ9 normalised time-activity curves for most relevant abdominal organs. The organ activity was normalised to the patient
administered activity. Coloured squares indicate patient-related data points. Blue dots indicate the normalised activity (mean ± SD) obtained at each
time point. The coefficient of determination (R2) of the mono-exponential fit (except for the gallbladder, see methods) is reported for each organ. Due
to previous surgery, gallbladder and pancreatic normalised time-activity curves were available for two and four patients only, respectively
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Previously published papers on dosimetry of bombesin
analogues were hardly comparable as they used various
radionuclides, including 99mTc [28, 29], 64Cu [31], 18F
[32] or 68Ga [30, 33, 34], different tracer molecules, dif-
ferent study subjects and dosimetry methodologies.
Organ-absorbed dose estimations were heterogeneous
even among studies using 68Ga-labelled bombesin ana-
logues [30, 33, 34]. Absorbed doses of single organs var-
ied greatly between the present study and that of Zhang
et al. on the 68Ga-labelled GRPR agonist NOTA-
Aca-BBN [33]. As an example, based on the results ob-
tained with OLINDA/EXM 1.1 (Additional file 2: Table
S2), the absorbed dose to the gallbladder was three times
higher, whereas the absorbed dose to the pancreas was
368 times lower in [33] than in the present study. In
turn, our organ absorbed dose estimations were, on
average, about 70 times higher than those of Zhang et al.
[33] (full data not shown). Nevertheless, EDs for refer-
ence person were similar: 2.76E-02 vs 3.1E-02 mSv/MBq
in [33] and the present study, respectively. This can be
attributed to the fact that organs with the highest wT,
such as the gonads (wT = 0.2), received nearly similar
doses in both studies.
Although obtained on healthy individuals, the
organ-absorbed dose estimations found by Roivainen et
al. [30] and by a further publication of Zhang et al. [34]
were in the same order of magnitude as ours. These
studies were conducted using the 68Ga-labelled antago-
nists DOTA-BAY 86-7548 [30] and NOTA-RM26 [34],
respectively. A dosimetry comparison with the present
study for most relevant parenchymal organs and bone
marrow is given in Fig. 4. In our study, the estimated ED
for male was lower than in [30] and [34] (2.79E-02 vs
3.8E-02 vs 6.57E-02 mSv/MBq in the present study, in
[30] and in [34], respectively, 1-h voiding cycle).
Discussion
GRPR, also known as BB2, is receiving great attention as a
theranostic target. The most exploited field of application
of GRPR-targeting peptides is prostate cancer, although
bombesin analogues might be relevant for other highly
prevalent tumours [9]. In the work-up of prostate cancer,
radiolabelled bombesin analogues might complement other
diagnostic probes, such as 18F-choline, 11C-acetate or
68Ga-PSMA, or even compete with them [15, 38]. As
regards therapeutic applications, radiolabelled bombesin
analogues might be advantageous because of the lack of sig-
nificant uptake by the lacrimal or salivary glands, which is
of serious concern in radionuclide therapy with PSMA [39].
Among several GRPR-targeting imaging probes, the
statin-based antagonist 68Ga-NODAGA-MJ9 has shown
favourable binding properties and has the advantage of
being labelled with high efficiency at room temperature
[16]. In the present study, we have assessed the dosim-
etry of 68Ga-NODAGA-MJ9 in five patients with relaps-
ing prostate adenocarcinoma. We discuss our results
below, with a particular focus on the comparison with
similar studies on bombesin analogues and on other
theragnostic peptides.
The single organ receiving the highest absorbed dose
was the pancreas (260 μGy/MBq). This is in agreement
with the notion that pancreas is probably the organ ex-
pressing the highest amount of GRPR [5], and in line
with previous studies on biodistribution and dosimetry
of radiolabelled bombesin analogues in mice [40] and in
humans [30, 31, 34].
Although relatively high, such absorbed doses are unlikely
to produce clinically relevant pancreatic toxicities in case of
therapeutic administrations of radiolabelled bombesin ana-
logues. In fact, we estimated that the absorbed dose to the
pancreas would be 1.85 Gy for the administration of a
Fig. 3 Biological organ kinetic of 68Ga-NODAGA-MJ9 corrected for 68Ga physical decay. Colour bars represent the average percent of injected
activity per gram of tissue (%IA/g) ± 1SD, for each time point
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theoretical 177Lu-labelled MJ9 compound given at a stand-
ard therapeutic activity of 7.4 GBq (Additional file 3: Table
S3). This theoretical estimation, although artificially ob-
tained from our measured 68Ga-based organ biokinetics,
can be considered largely safe as no relevant pancreatic tox-
icity has been observed for absorbed doses that are at least
one order of magnitude higher in external beam radiother-
apy which, although not optimal, is presently our only term
of comparison [41, 42].
Of note, two previous PET-based dosimetry studies re-
ported substantially inferior radiation absorbed doses to
the pancreas after the injection of 18F-BAY 864367 [32]
and 68Ga-NOTA-Aca-BBN [33] (14.36 μGy/MBq and
1.05 μGy/MBq, respectively). These results are
questionable, as the pancreas clearly shows a prominent
uptake on the PET images featured by these publications
[32, 33]. In the striking case of [33], the radiation-absorbed
dose reported for the pancreas was even lower than that
reported for the muscle (1.39 μGy/MBq). These important
discrepancies are unlikely justified by different tracer kinet-
ics; rather they are probably due to different methodolo-
gies used for dose calculations. This highlights the need
Table 2 Residence times, organ-absorbed doses and ED according to OLINDA/EXM 2.0 for 30-min and 1-h urinary voiding cycles in
men. Extrapolated organ-absorbed doses in female and reference person are reported for 1-h urinary voiding cycle only
Target organ Patient cohort (n = 5 male)
Residence time (h) Male Male Female Reference
0.5 h voiding 1 h voiding 1 h voiding 1 h voiding
Mean SD Dose SD Dose SD Dose Dose
mGy/MBq mGy/MBq mGy/MBq mGy/MBq
Adrenals 2.48E-04 8.49E-05 1.48E-02 2.22E-03 1.46E-02 2.13E-03 1.57E-02 1.52E-02
Brain 1.53E-03 1.05E-03 1.71E-03 3.12E-04 1.71E-03 3.20E-04 3.62E-03 2.68E-03
Breast – – – – – – 1.06E-02 1.06E-02
Esophagus – – 1.06E-02 5.47E-04 1.06E-02 5.22E-04 1.25E-02 1.16E-02
Eyes – – 8.39E-03 4.70E-04 8.39E-03 4.56E-04 1.02E-02 9.32E-03
Gallbladder walla 3.60E-03 1.27E-03 2.69E-02 5.59E-03 2.69E-02 5.66E-03 2.19E-02 1.99E-02
Left colon 6.73E-03 3.33E-03 3.37E-02 9.04E-03 3.38E-02 9.01E-03 3.27E-02 3.08E-02
Small Intestinea 4.01E-02 1.71E-02 3.88E-02 1.05E-02 3.90E-02 1.04E-02 4.04E-02 3.76E-02
Stomach walla 4.79E-03 2.45E-03 1.92E-02 1.53E-03 1.92E-02 1.53E-03 2.00E-02 1.91E-02
Right colon 1.35E-02 6.66E-03 3.21E-02 1.01E-02 3.22E-02 1.01E-02 3.28E-02 3.00E-02
Rectum 6.73E-03 3.33E-03 3.18E-02 1.02E-02 3.25E-02 9.84E-03 3.58E-02 3.17E-02
Heart walla 2.16E-02 5.45E-03 2.13E-02 2.26E-03 2.13E-02 2.26E-03 2.70E-02 2.42E-02
Kidneys 2.14E-02 2.23E-03 3.48E-02 3.04E-03 3.48E-02 3.03E-03 3.31E-02 3.40E-02
Liver 3.79E-02 2.93E-03 1.41E-02 8.41E-04 1.41E-02 8.41E-04 1.85E-02 1.63E-02
Lungs 2.88E-02 5.98E-03 1.34E-02 1.95E-03 1.34E-02 1.95E-03 1.66E-02 1.50E-02
Ovaries – – – – – – 1.50E-02 1.49E-02
Pancreas 8.13E-02 1.95E-02 2.60E-01 6.14E-02 2.60E-01 6.14E-02 2.43E-01 –
Prostate – – 1.22E-02 5.52E-04 1.33E-02 7.91E-04 – 1.33E-02
Salivary glands – – 9.12E-03 5.06E-04 9.12E-03 4.93E-04 1.07E-02 9.93E-03
Red marrow 7.10E-03 8.59E-04 9.38E-03 4.18E-04 9.49E-03 4.06E-04 1.17E-02 1.17E-02
Osteogenic cells – – 6.83E-03 3.23E-04 6.89E-03 3.21E-04 7.71E-03 7.87E-03
Spleen 3.16E-03 6.73E-04 1.37E-02 1.58E-03 1.37E-02 1.58E-03 1.55E-02 1.46E-02
Testes – – 9.56E-03 5.28E-04 9.82E-03 5.59E-04 – 9.82E-03
Thymus – – 1.02E-02 3.99E-04 1.02E-02 3.60E-04 1.29E-02 1.15E-02
Thyroid 3.20E-04 5.00E-05 9.32E-03 8.30E-04 9.15E-03 8.21E-04 1.05E-02 9.85E-03
Urinary bladder walla 8.77E-02 1.69E-02 6.98E-02 1.26E-02 1.12E-01 1.97E-02 1.39E-01 1.25E-01
Uterus – – – – – – 1.78E-02 1.76E-02
Total body – – 1.14E-02 5.24E-04 1.17E-02 5.87E-04 1.43E-02 1.30E-02
ED ICRP 103 (mSv/MBq) – – 1.76E-02 1.07E-03 1.88E-02 1.16E-03 2.30E-02 2.17E-02
aIrradiation from the organ content is accounted for residence time calculation
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for a standardisation of methodology and data reporting in
clinical dosimetry procedures.
The absorbed dose to the kidneys resulted to be
34.8 μGy/MBq for 68Ga-NODAGA-MJ9, which is lower
than that estimated for other 68Ga-labelled peptides,
such as PSMA or somatostatin analogues [43–47]. Over-
all, these studies showed absorbed doses to the kidneys
ranging from 89 to 262 μGy/MBq [43–47].
In the present study, by assuming a urinary voiding
interval of 1 h, we calculated an ED of 18.8 μSv/MBq in
men, which would correspond to 2.8 mSv after a tracer
injection of 150 MBq 68Ga-NODAGA-MJ9. This esti-
mated ED falls within the range 16.7–25.7 μSv/MBq re-
ported for other 68Ga-labelled peptides [43–47].
However, differently from previous studies, our absorbed
dose calculations were based on OLINDA/EXM 2.0. If
the absorbed dose estimation is made with OLINDA/
EXM 1.1, the ED in male increases up to 27.9 μSv/MBq
for 68Ga-NODAGA-MJ9. The lower ED estimated with
OLINDA/EXM 2.0 can be explained, in first instance, by
a lower tissue wT attributed to the most irradiated organ,
that is the pancreas in our case (wT pancreas = 0.025
vs. 0.0092 in OLINDA/EXM 1.1 and OLINDA/EXM
2.0, respectively) [24]. Secondarily, the phantoms im-
plemented in OLINDA/EXM 1.1 and OLINDA/EXM
2.0 consider two different organ masses for the pan-
creas (94.3 g vs. 140 g in OLINDA/EXM 1.1 and
OLINDA/EXM 2.0 respectively), which has an add-
itional impact on the calculation of the ED. Conse-
quently, in our specific case of 68Ga-NODAGA-MJ9,
the equivalent dose to the pancreas accounts for 35% of
the ED in OLINDA/EXM 1.1, whereas it accounts for
only 13% of the ED in OLINDA/EXM 2.0.
As discussed by some authors [43, 48], in OLINDA/
EXM 2.0, EDs would be lower compared to OLINDA/
EXM 1.1 for both 68Ga-labelled PSMAs and
somatostatin analogues, as well. Therefore, whatever
version of OLINDA/EXM is used, ED is slightly higher
for 68Ga-NODAGA-MJ9 than for 68Ga-labelled PSMAs
or somatostatin analogues.
This study has inherent limitations due to the small
number of patients. Moreover, by chance, one patient
had history of pancreatic carcinoma treated with pan-
creaticoduodenectomy, and two additional patients had
their gallbladder surgically removed for gallstones. This
has further reduced the number of our observations.
In addition, dosimetry data regarding prostate gland
have probably little clinical significance in the context of
our study. In fact, we enrolled only patients who had their
prostate surgically removed, so that absorbed doses to the
prostate have been estimated by the software considering
only the contribution of neighbouring organs as sources
of radiation. Analogously, our extrapolation to female dos-
imetry should be interpreted with caution, especially con-
cerning the estimated absorbed dose to breast and
reproductive organs. Nevertheless, the dosimetry calcula-
tion for female subject is required in order to calculate the
ED which, according to the ICRP103 methodology [24], is
based on both male and female organ equivalent dose
ponderation.
Conclusions
We have performed the first human dosimetry of
68Ga-NODAGA-MJ9. Our data shows the pancreas to
be the most irradiated organ in 68Ga-NODAGA-MJ9
diagnostic procedures, followed by the urinary bladder
wall, the small intestine, and the kidneys. ED is in the
same range of other common 68Ga-labelled peptides.
The differences of dosimetry results between the present
study and other previous works on radiolabelled bombe-
sin analogues mainly depend on the methodology used
for absorbed dose calculations.
Fig. 4 Dosimetry comparison between our study and those of Roivainen et al. [30] and Zhang et al. [34] based on OLINDA/EXM 1.0. The
absorbed dose estimations reported in this figure are based on either a 3.5-h urinary voiding cycle (our study and that of Roivainen et al. [30]) or
on a 1-h voiding cycle (Zhang et al. [34]). It should be noted that, for the organs reported, variations of urinary voiding cycle do not produce
significant changes of absorbed dose estimations. Error bars represent ± 2SD
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